<DOC>
	<DOCNO>NCT01943799</DOCNO>
	<brief_summary>This study evaluate safety efficacy GS-4774 adult chronic hepatitis B ( CHB ) viral infection virally suppress oral antiviral medication . Participants randomize 1:2:2:2 ratio treatment arm 20 week .</brief_summary>
	<brief_title>Safety Efficacy GS-4774 Treatment Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Ability understand sign write informed consent form , must obtain prior initiation study procedure Currently take HBV oral antiviral medication Documented evidence chronic HBV infection ( eg , HBsAg positive 6 month ) Virallysuppressed ( HBV DNA low limit quantification ( LLOQ ) â‰¥ 1 year ) Cirrhosis Inadequate liver function Coinfection hepatitic C virus ( HCV ) , HIV hepatitic D virus ( HDV ) Evidence hepatocellular carcinoma Significant cardiovascular , pulmonary , neurological disease Females pregnant may wish become pregnant study Received solid organ bone marrow transplant Use another investigational agent within 3 month screen Current alcohol substance abuse judge investigator potentially interfere compliance History demyelinate disease ( GuillainBarre ) , Bell 's Palsy , Crohn 's disease ulcerative colitis , autoimmune disease Known hypersensitivity study drug , metabolites formulation excipients Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( basal cell skin cancer , etc ) . Participants evaluation possible malignancy eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hepatitis B ( HBV )</keyword>
	<keyword>Oral antiviral ( OAV )</keyword>
	<keyword>GS-4774</keyword>
</DOC>